Stem Cell Transplant or Cellular Therapy - Allogeneic

Allogeneic

AML/MDS/ALL

MDS Only

AML Only

AML/MDS Only

Severe Aplastic Anemia

Multiple Diseases

Key

Open for Enrollment
In Development
Enrollment on Hold

IRB# 10146 Compares reduced intensity allogeneic stem cell transplant to hypomethylating therapy or best supportive care in patients aged 50-75 with intermediate - 2 and high risk myelodysplastic syndrome.

IRB# 17622 Tests the drug Gilteritinib with a placebo for AML with a FLT3/ITD mutation after allogeneic transplant.

IRB# 16995 Tests the drug PRO 140 compared to placebo to prevent Graft vs. Host Disease in AML and MDS patients undergoing allogeneic stem cell transplants.

IRB# 16189 Phase I/phase 2 study of ProTmune ex vivo mobilized peripheral blood cells.

IRB# 18142 Safety and Efficacy study of ATIR101 Compared to Post-transplant Cyclophosphamide for the prevention of GVHD in a haploidentical transplant (HATCY).

IRB# 16943 BMT CTN phase II study of ATG-based conditioning regimens for haploidentical and cord blood transplants.

IRB# 16982 Donor T-Cell infusion for adults with recurrent minimal residual disease post HSCT.

IRB# 18301 Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients.

10/31/2018

http://www.ohsu.edu/research/rda/so/knight.php